United States: Riddle Me This: The Federal Circuit Provides A Measure Of Clarity To The Enigmatic Biosimilar Approval Pathway

In Amgen Inc. v. Sandoz Inc. (No. 2015-1499), a fractured panel of the Federal Circuit Court of Appeals recently decided two issues of first impression relating to the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), the statutory scheme establishing an abbreviated pathway for regulatory approval of follow-on biological products.  Both the biosimilar applicant (Sandoz) and the reference product sponsor (Amgen) emerged partly victorious, with one two-judge majority agreeing with Sandoz that a biosimilar applicant is not required to disclose its application and manufacturing process to the reference product sponsor, and a different two-judge majority agreeing with Amgen that a biosimilar applicant cannot provide the required 180-day notice of commercial marketing prior to FDA approval, or "licensing," of the biosimilar product.  All three members of the panel joined together, however, in calling out the complexity of the BPCIA, likening it—as Winston Churchill once said of Russia—to "a riddle wrapped in a mystery inside an enigma."

The BPCIA establishes an abbreviated pathway, analogous to that created by the Hatch-Waxman Act for generic pharmaceutical drugs, that allows a company to seek regulatory approval for a follow-on biological product without the rigor required of the original biologics license.  Whereas a biologics license application ("BLA") requires extensive clinical data establishing the safety and efficacy of the original product, an abbreviated biologics license application ("aBLA") requires only that the follow-on applicant (also known as a "subsection (k) applicant") establish that its product is either "biosimilar" to or "interchangeable" with the previously licensed biologic (known as the "reference product").  Compare 42 U.S.C. § 262(a) with id. § 262(k).  However, Congress also provided a twelve-year period of exclusivity for the reference product from the date of its first licensure, such that no follow-on product may be sold during that interval, regardless of patent protection.  Id. § 262(k)(7)(A).  In fact, an application for a biosimilar cannot even be submitted until four years after first licensure of the reference product.  Id. § 262(k)(7)(B).  In this way, the BPCIA seeks to balance the interests of those engaging in original biologics discovery with the public's desire for lower cost medical treatment.

The BPCIA also establishes a regime for the reference product sponsor and subsection (k) applicant to narrow and resolve patent infringement disputes.  In addition to creating an artificial act of infringement, again not unlike that created by the Hatch-Waxman Act for generic pharmaceutical drugs, the BPCIA also establishes a complex process, often referred to as the "patent dance," for the exchange of information between the subsection (k) applicant and reference product sponsor.  See generally 42 U.S.C. § 262(l).  First, within 20 days after an aBLA is accepted by the FDA for review, the BPCIA specifies that a subsection (k) applicant "shall provide to the reference product sponsor a copy of the application submitted . . . under subsection (k), and such other information that describes the process or processes used to manufacture the biological product that is the subject of such application."  Id. § 262(l)(2)(A).  Subsequent to that exchange, the BPCIA also establishes a schedule for the parties to provide each other with lists of patents they believe applicable, along with their respective positions on infringement and validity.  Id. § 262(l)(3).  The BPCIA then allows the reference product sponsor to bring an action for patent infringement.  Id. § 262(l)(6).  Finally, a subsection (k) applicant "shall provide notice to the reference product sponsor not later than 180 days before the date of first commercial marketing of the biological product licensed under subsection (k)," thus allowing the reference product sponsor to seek a preliminary injunction prohibiting such activity pursuant to any patent listed by either party as part of the patent dance but excluded from the § 262(l)(6) infringement action.  Id. § 262(l)(8)(A)–(B).

Amgen began marketing the biological product filgrastim, branded Neupogen®, in 1991.  Sandoz filed an aBLA in May 2014 seeking approval for a biosimilar version of filgrastim and, upon receiving notification from the FDA that its aBLA had been accepted for review, notified Amgen on July 8, 2014 that it intended to launch its biosimilar immediately upon FDA approval of the follow-on product.  When Sandoz shortly thereafter elected not to engage in the patent dance, Amgen brought suit in the Northern District of California asserting claims of unfair competition and conversion under California state law, premised on Amgen's allegation that Sandoz violated the BPCIA by failing to disclose its aBLA and manufacturing information and by prematurely providing notice of commercial marketing prior to licensure by the FDA.  Amgen also claimed infringement of its U.S. Patent No. 6,162,427, which claims a method of using filgrastim, under federal law.  The FDA approved the aBLA filed by Sandoz on March 6, 2015, on which day Sandoz (again) provided notice of commercial marketing to Amgen.

The district court agreed with Sandoz's interpretation of the BPCIA, holding that the subsection (k) provision regarding the exchange of information was permissive and not mandatory and further that Sandoz's notice of its intent to commercially market a filgrastim follow-on product was effective despite being given prior to the FDA's approval.  After the district court dismissed Amgen's unfair competition and conversion claims and entered final judgment as to that portion of the case, Amgen appealed.

On the first issue, the first panel majority, consisting of Judges Lourie and Chen, agreed with the district court that a follow-on applicant is not required to engage in the patent dance.  That majority found that when read in context, the word "shall" in paragraph (l)(2)(A) cannot mean "must" because the BPCIA elsewhere contemplates that a subsection (k) applicant may fail to disclose the information detailed in paragraph (l)(2)(A).  Specifically, paragraph (l)(9)(C) provides a remedy for a subsection (k) applicant's failure to comply with paragraph (l)(2)(A), pursuant to which the reference product sponsor may bring an action for declaratory judgment on any patent.  The first majority noted that this would allow the reference product sponsor to obtain the same information specified in paragraph (l)(2)(A) through discovery, which in point of fact Amgen had already done.  The majority thus concluded that because Sandoz had taken "a path expressly contemplated by the BPCIA, it did not violate the BPCIA by not disclosing its aBLA and the manufacturing information by the statutory deadline."

With respect to the timing of a subsection (k) applicant's notice of commercial marketing, the second panel majority, consisting of Judges Lourie and Newman, concluded that the district court had erred in holding that such notice may be given prior to FDA approval of a biosimilar product.  Instead, the panel majority found that the statutory language compelled an interpretation pursuant to which effective notice can be given only after a biosimilar product has been licensed by the FDA.  In particular, the majority relied on Congress's use of the term "biological product licensed under subsection (k)" in paragraph (l)(8)(A), in contrast to other BPCIA provisions that instead use the term "the biological product that is the subject of" the application, reasoning that Congress used "licensed" instead of "subject of" because it intended a different meaning.  By requiring that final FDA approval be granted prior to any notice of commercial marketing, Congress sought to ensure that any controversy between the subsection (k) applicant and reference product sponsor would be "fully crystallized," and thus that the reference product sponsor would not be "left to guess the scope of the approved license and when commercial marketing would actually begin."  The second majority therefore concluded that "under paragraph (l)(8)(A), a subsection (k) applicant may only give effective notice of commercial marketing after the FDA has licensed its product."

It remains to be seen how long the panel's guidance on these two issues of first impression remains dispositive, as the fractured decision reveals conflicting judicial opinions that may convince the Federal Circuit to engage in en banc review if requested by either party.  In the meantime, neither brand-name biologic companies nor biosimilar companies are left entirely happy.  Should other biosimilar companies follow in Sandoz's footsteps and refuse to share manufacturing information, brand-name biologic companies will be forced to rely on expensive litigation discovery procedures to fully understand which of their patent rights may even be applicable.  On the other hand, brand-name biologic companies may now gain an extra six months of exclusivity where FDA licensure of a biosimilar occurs towards the end of the statutory twelve-year term. Only time will tell whether the panel decision in Amgen v. Sandoz identified an effective solution to two of the many riddles posed by the BPCIA.​​​​​​​

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions